newsfilter
← Latest News
Business Wire·

Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson's Disease

Ipsen obtains the exclusive worldwide rights to develop and commercialize the investigational treatment mesdopetam which is based on a novel mechanism of action Mesdopetam, an oral dopamine D3-receptor antagonist, has completed Phase Ib and IIa